PROKIDNEY CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.48 USD | -17.14% |
|
+3.26% | +95.51% |
| 05-28 | Transcript : ProKidney Corp. - Special Call | |
| 05-10 | ProKidney Q1 Loss Unchanged From Year Earlier | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 222M 17.45B |
|---|---|---|---|---|---|
| Net income 2024 * | -146M -11.45B | Net income 2025 * | -43M -3.37B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 193M 15.13B | Net cash position 2025 * | 310M 24.35B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.72
x | P/E ratio 2025 * |
-4.85
x | Employees | 163 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.3% |
More Fundamentals
* Assessed data
More news
Latest transcript on ProKidney Corp.
More recommendations
More press releases
| 1 day | -17.14% | ||
| 1 week | +3.26% | ||
| 1 month | +61.86% | ||
| 3 months | +116.15% | ||
| 6 months | +106.53% | ||
| Current year | +95.51% |
1 week
3.27
4.35
1 month
2.114.44
Current year
1.184.44
1 year
1.1213.51
3 years
1.1214.19
5 years
1.1214.19
10 years
1.1214.19
| Managers | Title | Age | Since |
|---|---|---|---|
Bruce Culleton
CEO | Chief Executive Officer | 57 | 16/07/23 |
James Coulston
DFI | Director of Finance/CFO | 48 | 31/12/21 |
Joseph Stavas
CTO | Chief Tech/Sci/R&D Officer | 69 | 30/09/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Doyle
BRD | Director/Board Member | 61 | 31/12/21 |
Brian Pereira
BRD | Director/Board Member | 65 | 31/12/21 |
John Maraganore
BRD | Director/Board Member | 60 | 10/08/22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 3.48 | -17.14% | 565,687 |
| 30/05/24 | 4.2 | +6.06% | 675,503 |
| 29/05/24 | 3.96 | +6.74% | 1,178,068 |
| 28/05/24 | 3.71 | +10.09% | 594,957 |
End-of-day quote Nasdaq, May 30, 2024
More quotes
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patientâs own cells isolated from the patient intended for treatment. The Companyâs lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patientâs diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patientâs own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participantâs own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Calendar
03/06/2024
- Jefferies Global Healthcare Conference
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.48
USD
Average target price
6.333
USD
Spread / Average Target
+81.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +95.51% | 222M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- PROK Stock
